| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c2ff03c5af3feb781c1c80c5efa291 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate |
2011-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d20408ce9287da819c4541ebc66f520e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d15c37a171c8761aff59063763dc12de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bb0d3b7d92e6c7bd4a67e8865477666
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e94e3033814773b2435e96ba5807f0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_723d91f50f12d913c8b25efcabe29409 |
| publicationDate |
2013-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2550010-A1 |
| titleOfInvention |
Method and compositions to induce apoptosis of tumoral cells expressing shh |
| abstract |
The invention is relative to the use of an effective amount of an agonist of the CDO's apoptotic function for the preparation of a drug to induce cell apoptosis in a patient having tumoral cells bearing CDO and expressing SHH. The agonist may be a CDO fragment, a fusion protein comprising a CDO fragment, an antibody against SHH, or a siRNA which is capable of inhibiting SHH expression. The invention also concerns a pharmaceutical composition containing an agonist of the CDO's apoptotic function or a CDO polypeptide or an antibody specific to CDO, and an agonist of the PTC1's apoptotic function or a PTC1 polypeptide or an antibody specific to PTC1, and a pharmaceutically acceptable excipient or vehicle. |
| priorityDate |
2010-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |